

Carcinogenicity Bioassays of Vinyl Chloride

I. Research Plan and Early Results¹

CESARE MALTONI AND GIUSEPPE LEEEMINE

Istituto di Oncologia "F. Adlari" and Centro Tumori, Bologna, Italy

Received March 11, 1974

These investigations are concerned with determining the oncogenic potentialities of vinyl chloride (VC) in experimental animals. The effect of this compound is being studied in relation to various experimental factors, such as route of administration, dose level, length of treatment, species, strain, and age of the animals.

Preliminary results are presented. When given by inhalation, VC induces in rats, Zymbal gland carcinomas, nephroblastomas, and angiosarcomas of the liver and of other anatomical sites, and in mice, pulmonary adenomas, mammary carcinomas and liver angiosarcomas.

A direct relationship has been found between dose and length of treatment and neoplastic response.

Vinyl chloride (VC) ($\text{CH}_2 = \text{CHCl}$) is a chemical compound of increasing industrial importance. It is used in the production of polyvinyl chloride resin, as a copolymer in Saran and other plastics, as a chemical intermediate, as a solvent, and as a propellant, in the past, for a short period, it was also used as anaesthetic. It is at present produced at a rate of near 12 million tons per year.

The following population groups may be exposed to VC: (1) workers engaged in the production of polyvinyl chloride (PVC) and of VC and in the use of VC for other industrial purposes; (2) workers manufacturing PVC; (3) residents about factories producing PVC and VC, and (4) to a much lesser extent, people undergoing contact with resins made with VC, with materials containing these resins or consumer products containing VC, as some propellant sprays.

The present research includes a series of correlated and integrated experiments dealing with carcinogenicity bioassays of this monomer. This research followed the preliminary results of the pioneering work of P. L. Viola, presented at the X International Cancer Congress (Houston, 1970) and published in 1971 (Viola *et al.*, 1971).

Viola's results indicated that exposure to 30,000 ppm of VC, 4 hours a day, 5 times a week for 10 months, produced tumours in rats, and that these occurred in skin, lungs and bones.

Immediately after the report in Houston, we communicated with Professor Viola, who kindly put at our disposal the manuscript of his extensive report, then in press, and several slides of the tumours.

On the basis of his results and material, we reached the following conclusions.

¹This project has been supported by the European Cooperative Group (ECG) which includes Montedison (Italy), ICI (U. K.), Solvay (Belgium), Rhone-Progil (France).

- (1) Under Professor Viola's experimental conditions, VC definitely showed a carcinogenic effect on rats;
- (2) 30,000 ppm of VC was an extremely high level of exposure;
- (3) The tumours described as cutaneous arose from Zymbal glands, which in rats are responsive to a large spectrum of carcinogens: e.g., 2-acetyl-amino-fluorene (Wilson *et al.*, 1941), benzidine (Spitz *et al.*, 1950), 3,2-dimethyl-4-aminobiphenyl (Walpole *et al.*, 1952), 4-aminostilbenes (Haddow *et al.*, 1948), 9,10-dimethyl-1,2-benzanthracene (Geyer *et al.*, 1953), 3-methoxy-4-aminoazobenzene (Miller and Miller, 1961), urethan (Tannenbaum *et al.*, 1962), and others.
- (4) The pulmonary tumours were most likely metastases from Zymbal gland carcinomas. These lesions were in fact morphologically similar to the Zymbal gland carcinomas, and all were observed in animals bearing Zymbal gland tumours.

It appeared useful to further investigate the nature and extent of the carcinogenic effect of VC, with particular emphasis on experimental factors related to exposure, such as route, concentration, duration, continuity or intermittence, etc., which could give more direct information concerning the risk of occupational and environmental exposure, and other factors related to the animals studied, such as species, strain, sex, and age. For these reasons, we were contacted by Professor Bartalini, Director of the Health Services of Montedison who offered the support of his Company for an experimental study of the biological effect of VC. Montedison was soon joined by ICI, Solvay and Rhone-Progil.

MATERIALS AND METHODS

The construction of an apparatus for programmed and controlled exposure took several months. The chambers were designed to deliver concentrations varying from 30,000 ppm to 50 ppm and to simultaneously treat nearly 1200 experimental rodents. Basically, it is built of stainless steel and glass. The control of VC concentrations is by g.c. chromatography.

VC has been supplied by Montedison. Each batch has been analyzed in the chemical research laboratory of Montedison before use to assess its degree of purity (99.99%).

The experiments largely utilized Sprague-Dawley rats, Wistar rats, Swiss mice, and hamsters have also been used. All the animals, except the hamsters, have been bred in our Institute for years and, whatever their use, are all examined at death by complete autopsy, giving us extensive information concerning their current pathology.

The animals have been weaned and classified by sex when 4-5 weeks old, at which time they have been numbered by ear punch, and divided into groups by litter distribution. From weaning, the animals have been fed, *ad libitum*, an adequate commercial diet. During the period of treatment, the animals are housed in groups of 10 in stainless steel wire cages with a solid bottom of the same metal. After the period of experimental treatment, the animals are kept in groups of 5 in makrolon cages, with tops made of stainless steel wire. A

shallow
kept in .

Fourte
at the o
results. "

Experi

Experi
10,000, 6
for 12 n
as with
at 2500
10,000

Experi

Experi
the effe
the same
still show

Experi

This v
constant

Experi

Experi
in ano
higher n

Experi

This v
atmosph

Experi

Experi

Experi

This e
as in Ex

Experi

Experi
species,

Experi

This v
effect at

shallow layer of white wood shavings served as bedding. The animals were kept in a temperature controlled laboratory at 19–20°C.

Fourteen experiments have been started in sequence. Some were programmed at the onset. The need for others appeared on the basis of initial experimental results. The plan of the experiments is shown in Table 1.

Experiment 1

Experiment 1 was to investigate the effect of the atmospheric exposure to 10,000, 6000, 2500, 500, 250, and 50 ppm of VC, 4 hours daily, 5 days weekly, for 12 months. Two groups of animals were added as controls: one untreated, as with all the following experiments, and one treated with vinyl acetate (VA) at 2500 ppm, under the same conditions. This dose of VA appeared to be the maximum possible dose for a chronic exposure.

Experiment 2

Experiment 2 was performed to obtain data in a larger number of animals on the effect of doses between 250 and 50 ppm, i.e., 200, 150, and 100 ppm, under the same conditions as in Expt 1. It was begun after it became clear that 250 ppm still showed oncogenic effects.

Experiment 3

This was planned to study the effects of a shorter period of exposure, keeping constant the other conditions of Expt 1.

Experiment 4

Experiment 4 studies the effect of the same type of exposure as in Expt 1, in another species, i.e., mice. The treatment lasted 7 months in view of the higher mortality, and the shorter life span of the mice of our line.

Experiment 5

This was undertaken as a pilot investigation on the possible effects of the atmospheric exposure during pregnancy, on offspring.

Experiment 6

Experiment 6 reproduced the conditions of Viola's experiments.

Experiment 7

This experiment was designed to study the effects of the same type of exposure as in Expt 1 in another strain of rats, i.e., Wistar.

Experiment 8

Experiment 8 studies the effects of the same exposure as in Expt 1 in a third species, i.e., hamsters, for the same period as in Expt 4.

Experiment 9

This was planned to further assess whether or not inhalation of VC has any effect at a dose level of 50 ppm in experimental animals.

TABLE 1
PLAN OF THE EXPERIMENTS TO MARCH 11, 1974

No. of experiment	Route	Treatment		Animals								Length of experiments (weeks)
				Species	Strain	Age (weeks)	No.					
		Doses of VC	Length				♂	♀	Total	Per group		
BT1	Inhalation	10,000, 6,000, 2500, 500, 250, 50 ppm Untreated controls Treated controls: VA 2500 ppm	4 hours daily, 5 days weekly, 52 weeks	Rat	Sprague-Dawley	13	268	309	577	61-96	131	
BT2	Inhalation	200, 150, 100 ppm Untreated controls	4 hours daily, 5 days weekly, 52 weeks	Rat	Sprague-Dawley	13	280	265	545	120-185	35	
BT3	Inhalation	10,000, 6,000, 2500, 500, 250, 50 ppm Untreated controls	4 hours daily, 5 days weekly, 17 weeks	Rat	Sprague-Dawley	21	262	288	550	60-190	60	
BT4	Inhalation	10,000, 6,000, 2500, 500, 250, 50 ppm Untreated controls	4 hours daily, 5 days weekly, 30 weeks	Mouse	Swiss	11	250	260	510	60-150	35	
BT5	Trans-placental	10,000, 6,000 ppm	4 hours daily, 7 days of pregnancy	Rat	Sprague-Dawley	19 Breeders 12 days Embryos	110	36	146	30-54	69	
BT6	Inhalation	30,000 ppm	4 hours daily, 5 days weekly, 52 weeks	Rat	Sprague-Dawley	17	30	30	60	60	35	
BT7	Inhalation	10,000, 6,000, 2500, 500, 250, 50 ppm Untreated controls	4 hours daily, 5 days weekly, 52 weeks	Rat	Wistar	11	--	220	220	30-40	35	
BT8	Inhalation	10,000, 6,000, 2500, 500, 250, 50 ppm Untreated controls	4 hours daily, 5 days weekly, 50 weeks	Hamster	Golden	11	--	268	268	32-70	22	
BT9	Inhalation	50 ppm (f) Untreated controls (c)	4 hours daily, 5 days weekly, 52 weeks	Rat	Sprague-Dawley	11	200	200	400	100 (c) 300 (f)	7	
BT10	Inhalation	10,000, 6,000 ppm Untreated controls	4 hours daily, 5 days weekly, 5 weeks; 4 hours daily, 1 day weekly, 25 weeks; 1 hour daily, 4 days	Rat	Sprague-Dawley	11	420	420	840	120	7	

UCC 107044

BT7	Inhalation	10,000, 6000, 2500, 500, 250, 50 ppm Untreated controls	4 hours daily, 5 days weekly, 52 weeks	Rat	Wistar	11	--	220	220	30-40	35
BT8	Inhalation	10,000, 6000, 2500, 500, 250, 50 ppm Untreated controls	4 hours daily, 5 days weekly, 30 weeks	Hamster	Golden	11	--	268	268	32-70	22
BT9	Inhalation	50 ppm (f) Untreated controls (c)	4 hours daily, 5 days weekly, 52 weeks	Rat	Sprague-Dawley	11	200	200	400	100 (c) 300 (f)	7
BT10	Inhalation	10,000, 6000 ppm Untreated controls	4 hours daily, 5 days weekly, 5 weeks; 4 hours daily, 1 day weekly, 25 weeks; 1 hour daily, 4 days weekly, 25 weeks	Rat	Sprague-Dawley	11	420	420	840	120	7
BT11	Ingestion	16.6 mg; 3.32 mg; 50 mg/kg body weight in olive oil Controls: olive oil	5 times weekly, 52 weeks	Rat	Sprague-Dawley	13	160	160	320	80	7
BT12	Endo-peritoneal injection	4.25 mg in 1.0 cc olive oil Controls: 1.0 cc olive oil	4, 3, 2, times by two months, and once	Rat	Sprague-Dawley	13	150	150	300	60	7
BT13	Subcutaneous injection	4.25 mg in 1.0 cc olive oil Controls: 1.0 cc olive oil	1 injection	Rat	Sprague-Dawley	21	80	70	150	75	7
BT14	Inhalation	10,000, 6000 ppm	4 hours daily, 5 days weekly, 5 weeks	Rat	Sprague-Dawley	1 day	45	44	82	43-46	2

VINYL CHLORIDE CARCINOGENESIS

Experiment 10

Experiment 10 studies the effect of a high, but short and/intermittent atmospheric exposure.

Experiment 11

This was performed to evaluate possible effects of VC by ingestion. Doses have been chosen on the basis of early data on the release of VC from food containers made of PVC, and following suggestions of EEC.

Experiment 12

This experiment studies a third general route of exposure namely the peritoneal cavity.

Experiment 13

Experiment 13 was started to assess whether the VC acts on tissues directly or through metabolites.

Experiment 14

This experiment has been included to study the responsiveness of newborn animals.

The animals are examined weekly, and weighed every 2 weeks during the period of treatment, and monthly after the treatment is completed. All detectable gross pathological changes are recorded during examination. All animals are kept under observation until spontaneous death. Moribund animals are isolated, in order to avoid cannibalism.

A complete autopsy is made of every animal. Histological specimens include Zymbal glands, interscapular brown fat, salivary glands, tongue, lungs, liver, kidneys, spleen, stomach, different segments of the intestine, bladder, brain, bones of the legs and feet, and any other organ with pathological lesions. The tissues are fixed in alcohol, processed, sectioned, and routinely stained by hematoxylin and eosin and with Van Gieson's method, in selected cases, other staining techniques have also been used.

All animals exposed to the highest doses (30,000 and 10,000 ppm) with or without tumours, are examined radiologically, during treatment and/or at death. Moreover, radiological examinations are made of all animals bearing tumours, even if exposed to the lower doses.

RESULTS

Preliminary results and other current data of Expts BT1, BT3, and BT4 are given in Tables 2-4.

Special aspects of Expt BT5 and BT6 are discussed in the text. Insofar as the other experiments are concerned, results are awaited.

In Table 2 are listed the observations on the oncogenic effect of graded concentrations of VC within a range of 50-10,000 ppm. It is evident that the overall occurrence of tumours decreases with decreasing concentrations from 39% tumour

EXPERIMENT

Groups and treatment	Animals (Sprague Dawley rats)	
	Total	Survivors
I		
VA 2500 ppm	96	
II		
VC 10,000 ppm	69	
III		
VC 6000 ppm	72	—
IV		
VC 2500 ppm	74	
V		
VC 500 ppm	67	
VI		
VC 250 ppm	67	1
VII		
VC 50 ppm	64	3
VIII		
No treatment	68	1
Total	577	5

^a Metastases to lung.

^b Metastases to liver and/or to

^c Metastases to lung.

^d Angiosarcoma in subcutaneous

^e Two intra-abdominal angiosarcoma of neck.

^f One pulmonary angiosarcoma

^g One intra-abdominal angiosarcoma

^h Two Zymbal gland adenoma adenocarcinoma of ovary.

ⁱ Sebaceous gland carcinoma of

^j Zymbal gland adenoma.

^k Minimal deviation hepatoma

^l One Zymbal gland adenoma.

^m Total No. of tumours.

incidence at 10,000 ppm, 29 ppm, respectively. Fifty (7 limited number of animals s controls and in rats exposed blastomas and angiosarcom tumours. The development on the concentration of the of exposure. If exposure tim (Table 3) the number of tu

TABLE 2
EXPERIMENT BTL. RESULTS AFTER 131 WEEKS

Groups and treatment	Animals (Sprague-Dawley rats)		Animals with tumours					Total
	Total	Survivors	Zymbal glands carcinomas ^a No.	Nephroblastomas ^b No.	Angiosarcomas Liver ^c No.	Other sites ^d No.	Other type and/or site ^e No.	
I VA 2500 ppm	96	—	—	—	—	—	—	—
II VC 10,000 ppm	69	—	13	3	6	—	5 ^f	27
III VC 6000 ppm	72	—	5	3	11	1 ^g	1 ^h	21
IV VC 2500 ppm	74	—	2	6	9	3 ⁱ	1 ^j	21
V VC 500 ppm	67	—	3	3	7	2 ^k	1 ^l	16
VI VC 250 ppm	67	1	—	5	2	2 ^m	2 ⁿ	11
VII VC 50 ppm	64	3	—	—	—	—	—	—
VIII No treatment	68	1	—	—	—	—	—	—
Total	577	5	23	20	35	8	10	96

^a Metastases to lung.

^b Metastases to liver and, or to lung and spleen.

^c Metastases to lung.

^d Angiosarcoma in subcutaneous fibrosing angioma.

^e Two intra-abdominal angiosarcomas (1 contiguous to spleen and 1 to ovary), 1 ossifying angiosarcoma of neck.

^f One pulmonary angiosarcoma; 1 angiosarcoma of uterus.

^g One intra-abdominal angiosarcoma (near to spleen); 1 intrathoracic ossifying angiosarcoma.

^h Two Zymbal gland adenomas, 1 neurilemmoma of the ear; 1 mammary carcinoma; 1 cystadenocarcinoma of ovary.

ⁱ Sebaceous gland carcinoma of skin.

^j Zymbal gland adenoma.

^k Minimal deviation hepatoma.

^l One Zymbal gland adenoma, 1 salivary gland carcinoma.

^m Total No. of tumours.

incidence at 10,000 ppm, 29% at 6000 and 2500 ppm to 24% and 16% at 500 and 250 ppm, respectively. Fifty (50) ppm did not cause tumour development in the limited number of animals so exposed, and no neoplasms were found in untreated controls and in rats exposed to VA 2500 ppm. Zymbal gland carcinomas, nephroblastomas and angiosarcomas of the liver and other sites were the prevailing tumours. The development of the latter 2 neoplasms was not always dependent on the concentration of the toxic agent, but to a higher degree on the duration of exposure. If exposure time was reduced from 52 weeks (Table 2) to 17 weeks (Table 3) the number of tumours after 60 weeks is markedly smaller; their per-

UCC 107047

TABLE 3
EXPERIMENT BT3 RESULTS AFTER 60 WEEKS^a

Groups and treatment	Animals (Sprague Dawley rats)		Animals with tumours					Total No.
	Total	Survivors	Zymbal glands carcinomas No.	Nephroblastomas No.	Angiosarcomas		Other type and/or site No.	
					Liver No.	Other sites No.		
I								
VC 10,000 ppm	60	36	3 (11)	— (1)	— (1)	—	— (4)	3 (17)
II								
VC 6000 ppm	60	48	1 (3)	(1)	(3)	(1)	—	1 (8)
III								
VC 2500 ppm	60	54	(2)	(1)	(1)		(1)	— (5)
IV								
VC 500 ppm	60	56	(1)		(1)		(1)	— (3)
V								
VC 250 ppm	60	44			(1)			— (1)
VI								
VC 50 ppm	60	50						—
VII								
No treatment	190	182				—	—	—
Total	550	471	4 (17)	(3)	(7)	— (1)	— (6)	4 (34)

^a Tumours found in experiment BT1 after 60 weeks are recorded in parenthesis.

^b Total No. of tumours.

centage is 5% at VC 10,000 ppm and 1.7% at 6000 ppm; at this time no tumours were found after administration of the lower concentrations. It is also worthy of note that all malignancies in this series were Zymbal gland carcinomas. After 35 weeks of exposure to 30,000 ppm (Expt BT6) 2 Zymbal gland carcinomas have been observed among 60 rats (58 survivors). In Expt BT5, two groups of 30 mature breeder rats were exposed to VC 10,000 ppm and 6000 ppm for 7 days during pregnancy. No tumours were observed after 69 weeks among the 28 survivors of each group. Angiosarcomas of the subcutaneous tissue occurred in their offspring; one tumour in one of the 54 rats of the 10,000 ppm group at the age of 24 weeks, the other tumor in one of the 36 animals of the 6000 ppm group was found at 22 weeks of age. Fifty and 30 rats, respectively, of the litters are still alive and under observation.

Table 4 indicates that mice respond to VC inhalation of 10,000-50 ppm in a similar manner as rats. While 50 ppm is again ineffective after 35 weeks, 30%, 15%, and 8.4% neoplasms were found after 10,000-6000, 2500-500, and 250 ppm, respectively. It is perhaps not surprising that in mice, pulmonary and mammary tumors were more frequent than other localizations, but the presence of angiosarcomas of the liver also occurred in this genus.

At present, 5 distinct types of tumours induced by VC have been observed; i.e., angiosarcomas, particularly of the liver (in rats and mice), nephroblastomas (in rats), Zymbal gland carcinomas (in rats) and pulmonary adenomas, some of

EXPERIMENT

AN
TUMORS

Treated

Groups and treatment	Treated	
	No.	%
I		
VC 10,000 ppm	30	30
II		
VC 6000 ppm	30	30
III		
VC 2500 ppm	30	30
IV		
VC 500 ppm	30	30
V		
VC 250 ppm	30	30
VI		
VC 50 ppm	30	30
VII		
No treatment	80	70
Total	260	250

^a In females.

^b One skin squamocellular carcinoma.

^c One skin squamocellular carcinoma.

^d Total No. of tumors.

which undergo malignant transformation. Macroscopic and microscopic findings are shown in Figs. 1-25.

The frequent Zymbal gland carcinomas are sometimes bilobated and can show different patterns (Fig. 2) appears often in a present various different histological types (Fig. 4^a), squamous, anaplastic, and metastases carry the characteristic of blastomas (Figs. 6-8) lead to the liver in rats (Figs. 11^a, 12^a), growth and hemorrhagic metastases (Fig. 15^a). Occasional blastoma occurred in the subcutaneous tissue appear generally as more or

^a Figures marked by asterisks.

UCC 107048

TABLE 4
EXPERIMENT B71: RESULTS AFTER 35 WEEKS

Other type and/or site No.	Total No. ^a	Animals (Swiss mice)						Animals with tumours				
		Treated			Survivors			Pulmo- nary tu- mours No.	Mam- mary carci- nomas ^b No.	Liver angio- sar- comas No.	Other type and/or site No.	Total No. ^c
		Groups and treatment	♂	♀	Total	♂	♀					
(4)	3 (17)	I										
		VC 10,000 ppm	30	30	60	6	18	24	12	1	2 ^d	19
	1 (8)	II										
		VC 6000 ppm	30	30	60	11	18	29	12	3	1	18
(1)	(5)	III										
		VC 2500 ppm	30	30	60	11	22	33	7	2		9
(1)	(3)	IV										
		VC 500 ppm	30	30	60	13	25	38	7		2	9
	(1)	V										
		VC 250 ppm	30	30	60	22	19	41	1	1		5
	—	VI										
		VC 50 ppm	30	30	60	13	24	37				—
	—	VII										
(6)	4 (34)	No treatment	80	70	150	61	61	122				—
		Total	260	250	510	137	187	324	12	10	3	60

^a In females.^b One skin squamocellular carcinoma, 1 skin invasive acanthoma, 1 subcutaneous hemangioma;^c One skin squamocellular carcinoma, 1 thymic lymphosarcoma.^d Total No. of tumors.

ne no tumours is also worthy cinomas. After nd carcinomas 5, two groups 6000 ppm for weeks among ous tissue oc- ie 10,000 ppm animals of the s respectively,

0-50 ppm in a ter 35 weeks, 2500-500, and ee, pulmonary tions, but the s. een observed; phroblastomas omas, some of

which undergo malignant transformation and mammary carcinomas (in mice).

Macroscopic and microscopic illustrations of the tumours induced are shown in Figs. 1-25.

The frequent Zymbal gland carcinomas can reach considerable size (Fig. 1*),² are sometimes bilobated and show a tendency to hemorrhages. Their structure can show different patterns. The arrangement of the normal Zymbal gland (Fig. 2) appears often in a disorganized form in the tumours. The carcinomas present various different histological patterns, e.g., glandular (Fig. 3), solid (Fig. 4*), squamous, anaplastic, and polymorphous. The frequent pulmonary metastases carry the characteristics of the primary lesion, (Fig. 5). The nephroblastomas (Figs. 6-8) lead to numerous metastases in the liver (Figs. 9*, 10*) but can also involve spleen and lungs. The frequently found angiosarcomas of the liver in rats (Figs. 11*, 12*, 13*, and 14) are characterized by the vascular growth and hemorrhagic appearance which is also present in pulmonary metastases (Fig. 15*). Occasionally, both angiosarcoma of the liver and nephroblastoma occurred in the same animal (Fig. 16*). Angiosarcomas of other sites appear generally as more or less hemorrhagic masses developing in the ab-

² Figures marked by asterisks (*) appear on the color plates

dominal cavity (Fig. 17), in the subcutaneous tissue (Fig. 22*) in the uterus (Fig. 18), or in the lung (Fig. 19). The ossifying angiosarcoma (Figs. 20*, 21*) and the salivary gland carcinoma (Figs. 23 and 24) occurred rarely (see Table 2, group VI). Figure 25 shows a liver angiosarcoma of a mouse.

CONCLUSIONS AND DISCUSSION

From the results presented in the tables, from the pathological and histological observations, the following early conclusions may be drawn.

- (1) VC is oncogenic under our experimental conditions. It induces, in rats, carcinomas of the Zymbal glands, nephroblastomas and angiosarcomas in liver and other sites; in mice, liver angiosarcomas, pulmonary adenomas and mammary carcinomas.
- (2) A direct relationship exists between the dose and length of treatment, and the neoplastic response.
- (3) Zymbal gland carcinomas and nephroblastomas may be bilateral.
- (4) Liver angiosarcomas are often multicentric.
- (5) Blood vessel ectasias and endothelial hyperplasia, associated or not with cellular atypia, are often observed in liver and in other organs and tissues in treated animals, with or without angiosarcomas. Therefore, the effect of VC on blood vessels and endothelia should be considered systemic.
- (6) The onset of 2 ossifying angiosarcomas suggests a new orientation in the pathogenetic interpretation of acroosteolysis in workers exposed to VC.
- (7) To the present no acroosteolytic lesions have been observed in our exposed animals.
- (8) No tumours have been observed in rats exposed to VA (2500 ppm).

Zymbal gland carcinomas, nephroblastomas and liver angiosarcomas have never been observed to occur spontaneously in our breed of Sprague-Dawley rats.

Although Zymbal glands, in rats, are responsive to a large number of carcinogens, only 3 spontaneously occurring cases of Zymbal gland carcinomas have been recorded in this species (Tannenbaum *et al.*, 1962). To our knowledge, no spontaneous nephroblastomas and liver angiosarcomas of rats have been reported

FIG. 1. Rat with Zymbal gland carcinoma.

FIG. 4. Zymbal gland carcinoma solid pattern, in rat. H-E $\times$ 158.

FIG. 9. Rat with nephroblastoma, metastases in liver.

FIG. 10. Liver metastasis from nephroblastoma, in rat. H-E $\times$ 158.

FIG. 11. Rat with liver angiosarcoma.

FIG. 12. Rat with liver angiosarcoma with lung metastasis.

FIG. 13. Liver angiosarcoma, characteristic pattern, in rat. H-E $\times$ 158.

FIG. 15. Pulmonary metastasis of liver angiosarcoma, in rat. H-E $\times$ 158.

FIG. 16. Liver angiosarcoma + nephroblastoma in rat.

FIG. 20. Laterocervical ossifying angiosarcoma, in rat. H-E $\times$ 158.

FIG. 21. Pulmonary metastasis of ossifying angiosarcoma, in rat. H-E $\times$ 40.

FIG. 22. Rat with subcutaneous angiosarcoma.



...the ...
...the ...
...the ...

...the ...

...the ...
...the ...
...the ...

...the ...

...the ...

...the ...
...the ...
...the ...

...the ...
...the ...

...the ...

...the ...

...the ...
...the ...

...the ...
...the ...
...the ...

...the ...

...the ...
...the ...

...the ...



...the ...



10



UCC 107051



UCC 107052



15



20



22




FIG. 2. Normal Zymbal gland of rat. H-E $\times 16$.




FIG. 3. Zymbal gland carcinoma, glandular pattern; in rat. H-E $\times 185$.



FIG. 5 Zymbal gland carcinoma, pulmonary metastasis, in rat, H-E $\times$ 46.



FIG. 7. Nephroblas



FIG. 6 Nephroblastoma in rat




FIG. 8. Nephroblastoma of a
H-E $\times$ 470

UCC 107054




FIG. 7. Nephroblastoma of rat, characteristic pattern; H-E $\times 185$.




FIG. 8. Nephroblastoma of a rat, nephrogenic blastema differentiating in a glomerulus H-E $\times 470$.

UCC 107055




FIG. 14. Liver angiosarcoma, characteristic pattern in a rat. H-E $\times 185$.




FIG. 17. Intra-abdominal angiosarcoma near the spleen in rat. H-E $\times 185$.



FIG. 18. Uterus :



FIG. 19. Angiosar.

UCC 107056



-E $\times 185$.




FIG. 18. Uterus angiosarcoma; in rat. II-I. $\times 470$.



-E $\times 185$.




FIG. 19. Angiosarcoma of lung, in rat. II-E $\times 185$.

UCC 107057



FIG. 23. Rat with salivary gland adenocarcinoma.




FIG. 24. Salivary gland adenocarcinoma in rat. H-E $\times$ 185.



FIG. 25. Liver

in literature and as far as is reported as being experimental.

Hepatic angiosarcomas have been reported in hamsters (Lee and Lee, 1968; Hadjiolov, 1973) and in hamsters (Tot been induced by *o*-aminoazobenzene and by *p*-dimethylaminobenzene. In the rabbit angiosarcoma (Speiser, 1954).

In man, angiosarcomas are reported as being collected to 1957 liver.

Induction of liver angiosarcoma follows a liver angiosarcoma follows. Cases of liver angiosarcoma thorotrast (MacMahon *et al.* 1965) and experimental.

The results of our investigation members of the European Commission a half ago, it became definite nephroblastomas and other to major American manufacturers.




FIG. 25. Liver angiosarcoma in a mouse, H-E $\times$ 185.

in literature and as far as we know, kidney nephroblastomas have never been reported as being experimentally induced.

Hepatic angiosarcomas have been experimentally induced in rats (Reuber and Lee, 1965; Hadjiolov, 1972), in mice (Roe and Salaman, 1954; Cardesa *et al.*, 1973) and in hamsters (Toth, 1972). In mice, extrahepatic angiosarcomas have been induced by *o*-aminoazotoluene (Andervont *et al.*, 1942; Andervont, 1950) and by *p*-dimethylaminobenzene, 1-azo-2-naphthalene (Muly and Saxén, 1953). In the rabbit, angiosarcomas have been produced by thorotrast (Zeitlhofer and Speiser, 1954).

In man, angiosarcomas are quite rare. One hundred-seventeen documented cases were collected to 1958 (Laidells, 1958), of which only 21 arose in the liver.

Induction of liver angiosarcomas have been reported in humans. In one case, a liver angiosarcoma followed the insertion of a radium needle (Ross, 1932). Cases of liver angiosarcomas have been reported following administration of thorotrast (MacMahon *et al.*, 1947; Lindu, 1953; Baserga *et al.*, 1960; Da Silva Horta *et al.*, 1965) and exposure to arsenic (Roth, 1957).

The results of our investigations have been periodically transmitted to the members of the European Cooperative Group. When, approximately a year and a half ago, it became definitely clear that VC was able to induce angiosarcomas, nephroblastomas and other malignancies, our results were also communicated to major American manufacturers of VC and PVC, to orient clinical observations

and epidemiological investigations, and to guide industrial hygiene measures needed for prevention of diseases which might be associated with VC exposure.

SUMMARY

This project of investigations is concerned with determining the oncogenic potentialities of vinyl chloride (VC). The effect of this compound is studied in relation to various experimental factors, such as route of administration, dose level, length of treatment, and species, strain and age of the animals.

The preliminary results are presented. When given by inhalation VC induces, in rats, Zymbal gland carcinomas, nephroblastomas and angiosarcomas of the liver and of other anatomical sites, and in mice, pulmonary adenomas, mammary carcinomas, and liver angiosarcomas.

A direct relationship between dose and length of treatment, and neoplastic response has been found.

REFERENCES

- ANDERVONT, H. B., GRADY, H. G., AND EDWARD, J. E. (1942). Induction of hepatic lesions, hepatomas, pulmonary tumors, and hemangio-endotheliomas in mice with *o*-aminotoluene. *J. Natl. Cancer Inst.* 3, 131-153.
- ANDERVONT, H. B. (1950). Induction of hemangio-endotheliomas and sarcomas in mice with *o*-aminotoluene. *J. Natl. Cancer Inst.* 10, 927-941.
- BASENGA, R., YOKOO, H., AND HENEGAR, G. C. (1960). Thorotrast-induced cancer in man. *Cancer* 13, 1021-1031.
- CARDESA, A., POUR, P., ALTHOFF, J., AND MOHR, U. (1973). Vascular tumors in female Swiss mice after intraperitoneal injection of dimethylnitrosamine. *J. Natl. Cancer Inst.* 51, 201-208.
- DA SILVA HORTA, Y., ABBAT, J. D., CAYOLLA DA MOTA, L., AND ROBEZ, M. L. (1965). Malignancies and other late effects following administration of thorotrast. *Lancet* 2, 201-205.
- GEYER, R. P., BRYANT, J. E., BLEISCH, V. R., PEIRCE, E. M., AND STARE, F. J. (1953). Effect of dose and hormones on tumor production in rats given emulsified 9,10-dimethyl-1,2-benzanthracene intravenously. *Cancer Res.* 13, 503-506.
- HADDOW, A., HARRIS, R. J. C., KON, G. A. R., AND ROE, F. M. F. (1948). The growth-inhibitory and carcinogenic properties of 4-aminostilbene and derivatives. *Phil. Trans. Roy. Soc. London, Ser. A* 241, 147-195.
- HADJILOV, D. (1972). Hemangioendothelial sarcomas of the liver in rats induced by diethylnitrosamine. *Neoplasma* 19, 111-114.
- LANDELLS, J. W. (1958). Malignant tumors of the heart and blood vessels. In (R. W. Raven, Ed.), "Cancer," Vol. 2, pp. 512-524. Butterworth, London.
- LUDIN, M. J. (1953). Haemangioendotheliomatose von Leber und Milz bei Thorotrast-speicherung. *Schweiz. Z. Allgem. Pathol.* 16, 987-994.
- MACMAHON, H. E., MURPHY, A. S., AND BATES, M. I. (1947). Endothelial-cell sarcoma of liver following thorotrast injections. *Amer. J. Pathol.* 23, 585-595.
- MILLER, J. A., AND MILLER, E. C. (1961). The carcinogenicity of 3-methoxy-4-aminobenzene and its N-methyl derivatives for extrahepatic tissues of the rat. *Cancer Res.* 21, 1068-1072.
- MULAY, A. S., AND SAXÉN, E. A. (1953). Lesions induced in mice by painting with *p*-dimethylaminoazobenzene-1-azo-2-naphthalene. *J. Natl. Cancer Inst.* 13, 1259-1273.
- REUBEN, M. B., AND LEE, C. W. (1966). Effect of age and sex on hepatic lesions in Buffalo strain rats ingesting diethylnitrosamine. *J. Natl. Cancer Inst.* 41, 1133-1140.
- ROE, F. J. C., AND SALAMAN, H. H. (1954). A quantitative study of the power and persistence of tumour-initiating. *Cancer* 8, 666-676.
- ROSS, J. M. (1932). A case ill. *Bacteriol.* 35, 899-912.
- ROTH, F. (1957). Arsen-Leber. 468-503.
- SPITZ, S., MAGUIGAN, W. H., AND dine. *Cancer* 3, 789-804.
- TANNENBAUM, A., VESSELINOVIC Multipotential carcinogenicity of Toth, B. (1972). Morphologic hydrazine dihydrochloride in Sy Viola, P. L. (1970). *Cancer Congress, Houston, Abstr. Vol.*
- VIOLA, P. L., BROTH, A., AND C and bones to vinyl chloride. C WALFORD, A. L., WILLIAMS, M. action of 4-aminodiphenyl and 255-263.
- WILSON, R. H., DE EDS, F., AND activity of 2-acetaminofluorene. ZEITHOFFER, J., AND SPEISER, P. experimenteller Thorotrast-veral

UCC 107060

gene measures
VC exposure.

the oncogenic
is studied in
istration, dose
als.

on VC induces,
rcomas of the
mas, mammary

and neoplastic

of hepatic lesions,
with o-aminoazo-

sarcomas in mice

-d cancer in man.

tumors in female
Cancer Inst. 51,

M. L. (1965).
Lancet 2, 201-

J. (1953). Ef-
9,10-dimethyl-1,2-

8) The growth-
ives. *Phil. Trans.*

rats induced by

essels. In (R. W.

ilz bei Thorotrast-

melial-cell sarcoma

3-methoxy-4-amino
t. *Cancer Res.* 21,

by painting with
13, 1259-1273.

hepatic lesions in
1, 1133-1140.

of the power and

persistence of tumour-initiating effect of ethyl carbamate (urethan) on mouse skin. *Brit. J. Cancer* 8, 666-676.

ROSS, J. M. (1932). A case illustrating the effects of prolonged action of radium. *J. Pathol. Bacteriol.* 35, 899-912.

ROTH, F. (1957). Arsen-Leber-Tumoren (Hamangioendotheliom). *Z. Krebsforsch.* 61, 468-503.

SPIZ, S., MAGUIGAN, W. H., AND DOBNER, K. (1950). The carcinogenic action of benzi-
dine. *Cancer* 3, 789-804.

TANNENBAUM, A., VESSELINOVICH, S. D., MALIONI, C., AND MITCHELL, D. S. (1962).
Multipotential carcinogenicity of urethan in Sprague-Dawley rat. *Cancer Res.* 22, 1362-1371.

TOTH, B. (1972). Morphological studies of angiosarcomas induced by 1,2-dimethyl-
hydrazine dihydrochloride in Syrian golden hamsters. *Cancer Res.* 32, 2818-2827.

VIOLA, P. L. (1970). Carcinogenic effect of vinyl chloride. X. *International Cancer
Congress, Houston, Abstr. Vol. 29.*

VIOLA, P. L., BIGOTTI, A., AND CAPUTO, A. (1971). Oncogenic response of rat skin, lungs
and bones to vinyl chloride. *Cancer Res.* 31, 516-519.

WALPOLE, A. L., WILLIAMS, M. H. G., AND BOWERS, D. C. (1952). The carcinogenic
action of 4-aminodiphenyl and 3-2'-dimethyl-4-aminodiphenyl. *Brit. J. Indust. Med.* 9,
255-263.

WILSON, R. H., DE EDS, F., AND COX, A. J., JR. (1941). The toxicity and carcinogenic
activity of 2-acetaminofluorene. *Cancer Res.* 1, 595-608.

ZEITLHOFFER, J., AND SPEISER, P. (1954). Hamangioendotheliomatose beim Kaninchen nach
experimenteller Thorotrast-verabreichung. *Z. Krebsforsch.* 60, 161-168.